PAT for the quarter stood at Rs 47.90 crore, supported by strong operational performance and rising test volumes.
Revenue came in at Rs 216.53 crore in Q2, marking a 22% YoY increase. Normalised EBITDA rose sharply by 49% YoY to Rs 75.36 crore, with consolidated EBITDA growing by 48% YoY. The company’s margins remained steady at 33%.
Gross margin stood healthy at 72%, reflecting operational efficiency and cost discipline.
The growth was driven by a 24% YoY rise in the Pathology segment. Within pathology, franchise revenue grew 20% YoY, while partnership revenue surged 35% YoY. Thyrocare processed 53.3 million tests during the quarter, a 21% YoY increase, reinforcing its position as India’s largest diagnostic test volume processor.
The company remains debt-free and holds net cash and cash equivalents exceeding Rs 190 crore. It also expanded its laboratory network by adding four new labs in Vijayawada, Bhagalpur, Roorkee, and Kashmir during H1 FY26.“We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare, coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India,” said Rahul Guha, MD & CEO of Thyrocare Technologies.Also read: LG share price target at Rs 2,050? Korean giant sparks record frenzy with 8 buy calls on Day 1
In addition to its financial performance, the Board approved a bonus share issue in the ratio of 2:1, i.e., two bonus shares for every one equity share held, subject to statutory approvals. The Board also declared an interim dividend of Rs 7 per equity share (pre-bonus), with the record date set for October 24.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
as a Reliable and Trusted News Source